2026 Q3 Portfolio Activity
In 2026 Q3, Boxer Capital Management, LLC maintained a portfolio of 75 distinct positions. The most significant new addition was ACHIEVE LIFE SCIENCE INC, now representing 1.51% of the total fund value. They heavily accumulated shares in SURROZEN INC, increasing the position by 23.1%. The fund also reduced its exposure to CAPRICOR THERAPEUTICS INC by 53.9%.
Position History
hover any row below to update
Loading…
Boxer Capital Management, LLC
AUM $1,151M
Total Positions
75
Quarter
2026 Q3
Top Holding
TNGX (22.8%)
Top 10 Concentration
71.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 75
Boxer Capital Management, LLC Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 22.82% | 25.61% |
#1
Prev: #1
|
6.5 |
—
|
-350,000 | -3.2% |
P
S
|
10,526,219 | $262,629,164 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KOD
KODIAK SCIENCES...
|
Healthcare | 12.17% | 4.34% |
#2
3
Prev: #5
|
6.5 |
—
|
no change | no change |
P
S
|
1,477,600 | $140,076,480 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 8.92% | 7.05% |
#3
1
Prev: #2
|
5.6 |
—
|
no change | no change |
P
S
|
500,000 | $102,630,000 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 5.10% | 3.71% |
#4
2
Prev: #6
|
5.0 |
—
|
95,451 | 22.2% |
P
S
|
524,551 | $58,639,556 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
REPL
REPLIMUNE GROUP...
|
Healthcare | 4.92% | 3.32% |
#5
3
Prev: #8
|
4.5 |
—
|
295,159 | 7.4% |
P
S
|
4,278,159 | $56,642,825 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 4.09% | 6.07% |
#6
3
Prev: #3
|
1.6 |
—
|
-130,029 | -21.5% |
P
S
|
474,971 | $47,031,628 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SRZN
SURROZEN INC
|
Healthcare | 3.81% | 2.03% |
#7
7
Prev: #14
|
4.0 |
—
|
255,000 | 23.1% |
P
S
|
1,360,683 | $43,786,778 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CORT
CORCEPT THERAPE...
|
Healthcare | 3.36% | 2.20% |
#8
5
Prev: #13
|
2.3 |
—
|
no change | no change |
P
S
|
335,500 | $38,659,665 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PGEN
PRECIGEN INC
|
Healthcare | 3.21% | 2.21% |
#9
3
Prev: #12
|
1.8 |
—
|
-829,661 | -16.1% |
P
S
|
4,320,339 | $36,982,101 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
QURE
UNIQURE NV
|
Healthcare | 2.99% | 5.21% |
#10
6
Prev: #4
|
1.7 |
—
|
-80,057 | -5.3% |
P
S
|
1,423,243 | $34,385,550 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 2.26% | 3.54% |
#11
4
Prev: #7
|
0.9 |
—
|
-314,885 | -31.5% |
P
S
|
683,615 | $26,018,386 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 2.26% | 1.08% |
#12
10
Prev: #22
|
2.9 |
—
|
93,153 | 11.6% |
P
S
|
893,153 | $25,990,752 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 2.19% | 0.67% |
#13
14
Prev: #27
|
3.9 |
—
|
183,054 | 183.1% |
P
S
|
283,054 | $25,200,297 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 2.08% | 1.57% |
#14
1
Prev: #15
|
1.8 |
—
|
no change | no change |
P
S
|
170,000 | $23,951,300 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CELC
CELCUITY INC
|
Healthcare | 1.98% | 3.28% |
#15
6
Prev: #9
|
0.8 |
—
|
-130,291 | -31.3% |
P
S
|
286,239 | $22,761,725 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IRD
OPUS GENETICS I...
|
Healthcare | 1.91% | 0.87% |
#16
8
Prev: #24
|
3.8 |
—
|
1,718,660 | 61.1% |
P
S
|
4,533,660 | $21,942,914 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
QTTB
Q32 BIO INC
|
Healthcare | 1.85% | 3.02% |
#17
7
Prev: #10
|
1.2 |
—
|
-571,668 | -18.2% |
P
S
|
2,577,642 | $21,317,099 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 1.77% | 1.39% |
#18
Prev: #18
|
1.7 |
—
|
no change | no change |
P
S
|
500,000 | $20,315,000 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ACHV
ACHIEVE LIFE SC...
|
Healthcare | 1.51% | — |
#19
Prev: #—
|
4.1 |
—
|
2,150,000 | — |
NEW
|
2,150,000 | $17,393,500 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CCCC
C4 THERAPEUTICS...
|
Healthcare | 1.20% | — |
#20
Prev: #—
|
4.0 |
—
|
4,150,000 | — |
NEW
|
4,150,000 | $13,819,500 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TRAX
FIRST TRACKS BI...
|
Healthcare | 0.74% | — |
#21
Prev: #—
|
3.8 |
—
|
240,000 | — |
NEW
|
240,000 | $8,505,600 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
STTK
SHATTUCK LABS I...
|
Healthcare | 0.70% | 0.52% |
#22
12
Prev: #34
|
2.3 |
—
|
175,396 | 17.5% |
P
S
|
1,175,396 | $8,016,200 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 0.69% | — |
#23
Prev: #—
|
3.8 |
—
|
2,500,000 | — |
NEW
|
2,500,000 | $7,925,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CGEM
CULLINAN THERAP...
|
Healthcare | 0.60% | — |
#24
Prev: #—
|
3.7 |
—
|
450,000 | — |
NEW
|
450,000 | $6,907,500 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CTNM
CONTINEUM THERA...
|
Healthcare | 0.58% | 0.61% |
#25
7
Prev: #32
|
1.2 |
—
|
no change | no change |
P
S
|
494,000 | $6,629,480 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 0.57% | 0.64% |
#26
3
Prev: #29
|
1.2 |
—
|
no change | no change |
P
S
|
100,000 | $6,591,000 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PALI
PALISADE BIO IN...
|
Healthcare | 0.56% | 0.76% |
#27
2
Prev: #25
|
1.2 |
—
|
no change | no change |
P
S
|
4,799,875 | $6,479,831 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CAPR
CAPRICOR THERAP...
|
Healthcare | 0.53% | 2.53% |
#28
17
Prev: #11
|
0.2 |
—
|
-752,319 | -53.9% |
P
S
|
642,837 | $6,087,666 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ETRA
ELECTRA THERAPE...
|
Healthcare | 0.44% | — |
#29
Prev: #—
|
3.7 |
—
|
450,000 | — |
NEW
|
450,000 | $5,062,500 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ANTX
AN2 THERAPEUTIC...
|
Healthcare | 0.44% | 0.27% |
#30
16
Prev: #46
|
2.7 |
—
|
195,000 | 26.0% |
P
S
|
944,035 | $5,022,266 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 0.41% | — |
#31
Prev: #—
|
3.7 |
—
|
175,465 | — |
NEW
|
175,465 | $4,769,138 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
EDSA
EDESA BIOTECH I...
|
Healthcare | 0.34% | 0.13% |
#32
25
Prev: #57
|
3.1 |
—
|
732,363 | 357.3% |
P
S
|
937,363 | $3,946,298 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 0.31% | 0.63% |
#33
3
Prev: #30
|
0.1 |
—
|
-250,000 | -55.6% |
P
S
|
200,000 | $3,610,000 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KZIA
KAZIA THERAPEUT...
|
Healthcare | 0.31% | 0.59% |
#34
1
Prev: #33
|
0.1 |
—
|
-188,500 | -33.7% |
P
S
|
371,500 | $3,564,542 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
ATTOVIA THERAPE...
|
|
Unknown | 0.30% | — |
#35
Prev: #—
|
3.6 |
—
|
200,000 | — |
NEW
|
200,000 | $3,428,000 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
PMVP
PMV PHARMACEUTI...
|
Healthcare | 0.30% | — |
#36
Prev: #—
|
3.6 |
—
|
2,050,000 | — |
NEW
|
2,050,000 | $3,423,500 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
CRESCENT BIOPHA...
|
|
Unknown | 0.29% | 0.62% |
#37
6
Prev: #31
|
0.1 |
—
|
-226,843 | -50.0% |
P
S
|
226,843 | $3,309,639 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
ZNTL
ZENTALIS PHARMA...
|
Healthcare | 0.24% | — |
#38
Prev: #—
|
3.6 |
—
|
1,013,555 | — |
NEW
|
1,013,555 | $2,807,547 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SRPT
SAREPTA THERAPE...
|
Healthcare | 0.24% | 0.20% |
#39
14
Prev: #53
|
1.1 |
—
|
no change | no change |
P
S
|
150,000 | $2,733,000 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ALLO
ALLOGENE THERAP...
|
Healthcare | 0.21% | 0.23% |
#40
9
Prev: #49
|
1.1 |
—
|
no change | no change |
P
S
|
1,500,000 | $2,400,000 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 0.21% | 0.18% |
#41
14
Prev: #55
|
1.1 |
—
|
no change | no change |
P
S
|
100,000 | $2,371,000 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SION
SIONNA THERAPEU...
|
Healthcare | 0.18% | — |
#42
Prev: #—
|
3.6 |
—
|
391,723 | — |
NEW
|
391,723 | $2,060,462 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CLNN
CLENE INC
|
Consumer Defensive | 0.17% | 0.22% |
#43
9
Prev: #52
|
1.1 |
—
|
no change | no change |
P
S
|
477,515 | $1,948,261 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ACRS
ACLARIS THERAPE...
|
Healthcare | 0.14% | — |
#44
Prev: #—
|
3.6 |
—
|
300,000 | — |
NEW
|
300,000 | $1,578,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MIST
MILESTONE PHARM...
|
Healthcare | 0.05% | 0.07% |
#45
15
Prev: #60
|
1.0 |
—
|
no change | no change |
P
S
|
666,666 | $577,132 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NMRA
NEUMORA THERAPE...
|
Healthcare | 0.05% | 0.26% |
#46
1
Prev: #47
|
0.0 |
—
|
-1,045,948 | -52.3% |
P
S
|
954,052 | $568,805 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KPTI
KARYOPHARM THER...
|
Healthcare | 0.01% | 0.22% |
#47
4
Prev: #51
|
0.0 |
—
|
-175,000 | -57.8% |
P
S
|
127,536 | $155,593 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SRZNW
SURROZEN INC
|
Unknown | 0.00% | 0.00% |
Sold All 😨
(Was: #63) |
0.0 |
—
|
-66,666 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RGNX
REGENXBIO INC
|
Healthcare | 0.00% | 0.01% |
Sold All 😨
(Was: #62) |
0.0 |
—
|
-15,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PEPG
PEPGEN INC
|
Healthcare | 0.00% | 0.04% |
Sold All 😨
(Was: #61) |
0.0 |
—
|
-272,892 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-50 of 75 holdings